

BEST AVAILABLE COPY

AN 1997-044618 [05] WPIDS  
CR 1998-448966 [39]  
DNC C1997-014283  
TI Antidiabetic compsn. comprises insulin sensitivity enhancer - in combination with e.g. alpha-glucosidase inhibitors, aldose reductase inhibitors, biguanide(s), statin cpds. and squalene synthesis inhibitors.  
DC B02 B03  
IN IKEDA, H; ODAKA, H; SOHDA, T  
PA (TAKE) TAKEDA CHEM IND LTD; (TAKE) TAKEDA YAKUHIN KOGYO KK  
CYC 29  
PI EP---749751 A2 19961227 (199705)\* EN 16p  
R: AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE  
CZ--9601811 A3 19970115 (199709)  
NO--9602606 A 19961223 (199709)  
AU--9656034 A 19970109 (199710)  
SK--9600794 A3 19970108 (199711)  
CA--2179584 A 19961221 (199716)  
JP--09067271 A 19970311 (199720) 14p <--  
EP---749751 A3 19970416 (199729)  
KR--97000233 A 19970121 (199801)  
HU--9601698 A2 19970528 (199803)  
ZA--9605190 A 19980225 (199813) 43p  
MX--9602399 A1 19970201 (199818)  
BR--1100755 A3 19980505 (199825)  
JP--10167986 A 19980623 (199835) 16p  
US--5952356 A 19990914 (199944)  
ADT EP---749751 A2 1996EP-0304570 19960620; CZ--9601811 A3 1996CZ-0001811 19960619; NO--9602606 A 1996NO-0002606 19960619; AU--9656034 A 1996AU-0056034 19960618; SK--9600794 A3 1996SK-0000794 19960618; CA--2179584 A 1996CA-2179584 19960620; JP--09067271 A 1996JP-0156725 19960618; EP---749751 A3 1996EP-0304570 19960620; KR--97000233 A 1996KR-0022615 19960620; HU--9601698 A2 1996HU-0001698 19960620; ZA--9605190 A 1996ZA-0005190 19960619; MX--9602399 A1 1996MX-0002399 19960619; BR--1100755 A3 1997BR-1100755 19970512; JP--10167986 A Div ex 1996JP-0156725 19960618, 1997JP-0360756 19960618; US--5952356 A 1996US-0667979 19960619  
PRAI 1995JP-0153500 19950620  
AN 1997-044618 [05] WPIDS  
CR 1998-448966 [39]  
AB EP 749751 A UPAB: 19981001  
Antidiabetic compsn. comprises an insulin sensitivity enhancer in combination with at least one of: an alpha-glucosidase inhibitor, an aldose reductase inhibitor, a biguanide, a statin cpd., a squalene synthesis inhibitor, a fibrate cpd., a LDL catabolism enhancer and an angiotensin converting enzyme inhibitor. Also claimed is a compsn. comprising a cpd. of formula (II) or its salts in combination with an insulin secretion enhancer and/or an insulin prepns. R'1 = opt. subst. hydrocarbon or heterocyclic gp.; Y = CO, CH(OH) or NR3; R3 = opt. subst. alkyl; m = 0 or 1; n = 0 or 1, 2; X = CH or N; A = a bond or 1-7C divalent aliphatic hydrocarbon gp.; Q = O or S; R1 = H or an alkyl gp.; ring E may opt. have further 1-4 substit. opt. combined with R1 to form a ring, provided that R1 does not represent benzopyranyl gp. when m and n = 0; X = CH; A = represents a bond; Q = S; R1, L and M = H and ring E does not have any further substs.  
USE - Compsn. has a potent depressive effect on diabetic hyperglycaemia and is useful in the prophylaxis or treatment of diabetes. The dosage of the insulin sensitivity enhancer is 0.01-10 (pref. 0.05-10, esp. 0.05-5) mg/kg or 0.005-10 (pref. 0.01-10, esp. 0.01-1) mg/kg, 1-3 times/day.  
ADVANTAGE - The compsn. does not cause adverse reactions (e.g. gastrointestinal disorders such as diarrhoea) even on long-term admin. and is effective for a large section of the diabetic population. The compsn. has a synergistic effect  
Dwg.0/0